This webinar will explore the expected benefits, toxicities and potential indications for the combination of immunotherapy and radiotherapy. Both are often used in the care of patients with non-small cell lung cancer, typically with non-overlapping indications for use. Topics will include the preclinical and clinical evidence and rationale for combining radiotherapy and immunotherapy. Target Audience: Physicians and researchers specializing in medical oncology, radiation oncology, pathology, pulmonary medicine and cancer research.

Faculty and Planners

• Corinne Faivre-Finn, FRCR MD PhD discloses she receives research funding from Astra Zeneca, MSD Pharmaceuticals and Elekta and is on an advisory board and scientific committees for Astra Zeneca.
• Shankar Siva, MBBS, FRANZCR, PhD discloses he is on an advisory board and is a consultant for Astra Zeneca and has a research grant from Varian Medical Systems.
• Willemijn S.M.E. Theelen, MD PhD discloses she is an investigator for Astra Zeneca.
• Kirsten Black, PhD, MPH has no financial relationships to disclose.
• Aubrey Shoe, MA has no financial relationships to disclose.

At the end of the webinar, learners will be able to:

• Understand the preclinical rationale for synergy in combining radiotherapy and immunotherapy.
• Understand the unresolved questions around sequencing, dose/fractionation, abscopal effects, and sites of irradiation in combination therapy.
• Understand pertinent clinical trial evidence for the safety and efficacy of radiotherapy and immunotherapy combinations.
• Update key ongoing trials of RT-IO combo in the curative, oligometastatic and metastatic setting.